ACTIVATED CHARCOAL CATEGORY I RECLASSIFICATION IS SUPPORTED by analysis of a new study, Requa Inc. contends in an Oct. 14 citizen petition submitted to FDA. Requa, manufacturer of Charcocaps, is seeking classification of activated charcoal as a Category I digestive aid for the indication of "relief of symptoms of gastrointestinal distress such as gas, pain, or cramps which occurs after eating." Activated charcoal was listed as Category III under a tentative final monograph issued Jan. 29, 1988. Requa said it "received assurance" from FDA at an October 1988 meeting "that one study attaining significant results would satisfy the requirements for upgrading the classification of activated charcoal." The company submitted a report, entitled "Study of Activated Charcoal Capsules in Decreasing Gastrointestinal Gas," that was based on a protocol "developed with input" from FDA, Requa said. The study, conducted by Mark Riggs, PhD, for Requa, analyzed 41 patients who consumed a gas-producing "test meal" and experienced symptoms within an hour. They were then randomized to receive two capsules of activated charcoal or placebo, with the opportunity for two more every half hour. Patients rated their symptoms every 10 minutes for two hours on a scale from 0 (none) to 3 (severe) in four categories: "Fullness or Bloating," "Pressure or Distension," "Pain and/or Cramping," and "Flatulence." The study found a statistically significant reduction in the mean duration of "Pain and/or Cramping" from 70 minutes on placebo to 30 with charcoal. Patient ratings of "overall symptom relief" were also higher for charcoal than for placebo. Other categories showed no significant differences. Riggs notes, however, that among patients entering the trial, "the overall trend . . . was for a predominance of more severe symptom history in the charcoal group." When a subgroup of patients with more severe past symptoms was analyzed, charcoal showed a significantly reduced median time to total relief. Requa also includes in its petition previously submitted trials attesting to the efficacy of activated charcoal. "These findings," Requa maintained, "provide ample support for reclassifying activated charcoal to a Category I digestive aid ingredient."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.
As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.
